Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.

被引：0
|
作者：
Zheng, Hanke
Yu, Tianzhou
Romley, John
Barzi, Afsaneh
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] City Hope AccessHope, Med Oncol & Therapeut, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23121
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102
    Hamauchi, S.
    Yamazaki, K.
    Masuishi, T.
    Kito, Y.
    Komori, A.
    Tsushima, T.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Fukutomi, A.
    Onozawa, Y.
    Muro, K.
    Yasui, H.
    Mori, K.
    Taniguchi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 50 - 51
  • [32] Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
    Jalali, A.
    Gard, G.
    Banks, S.
    Dunn, C.
    Wong, H. L.
    Wong, R.
    Lee, M.
    Gately, L.
    Loft, M.
    Shapiro, J. D.
    Kosmider, S.
    Tie, J.
    Ananda, S.
    Yeung, J. M.
    Jennens, R.
    Lee, B.
    McKendrick, J.
    Lim, L.
    Khattak, A.
    Gibbs, P.
    CURRENT PROBLEMS IN CANCER, 2022, 46 (02)
  • [33] Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
    Sales, C.
    Juliao, I.
    Rosinha, A.
    Marques, D.
    Carneiro, F.
    Faustino, C.
    Machado, M.
    Ferreira, P.
    Fragoso, M.
    Sousa, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 79 - 79
  • [34] A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiaochen
    Qiu, Huafeng
    Chen, Yunwang
    Wang, Mingxing
    Zhu, Pengfei
    Pan, Shuangyue
    Deng, Yaya
    Yang, Liu
    Chen, Zheling
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
    Su, Guan-Li
    Wang, Yuan-Yuan
    Wang, Jin-Cheng
    Liu, Hao
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (07)
  • [36] TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
    Eng, Cathy
    LANCET ONCOLOGY, 2020, 21 (03): : 326 - 327
  • [37] Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Kito, Yosuke
    Komori, Azusa
    Tsushima, Takahiro
    Narita, Yukiya
    Todaka, Akiko
    Ishihara, Makoto
    Yokota, Tomoya
    Tanaka, Tsutomu
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    Yasui, Hirofumi
    Mori, Keita
    Taniguchi, Hiroya
    CLINICAL COLORECTAL CANCER, 2017, 16 (01) : 51 - 57
  • [38] TAS-102 plus bevacizumah with metastatic colorectal cancer in salvage line
    Osawa, Hiroshi
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 : S23 - S23
  • [39] Review on TAS-102 development and its use for metastatic colorectal cancer
    Mota, Jose Mauricio
    Fonseca, Leonardo G.
    Braghiroli, Maria Ignez
    Hoff, Paulo M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 104 : 91 - 97
  • [40] TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
    Liu, Cheng-Jiang
    Hu, Ting
    Shao, Ping
    Chu, Wu-Yang
    Cao, Yu
    Zhang, Feng
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2021, 2021
12345